Danaher (NYSE:DHR) announced that it entered into a definitive agreement to acquire Aldevron for approximately $9.6 billion. Fargo, N.D.-based Aldevron, which employs approximately 600 people, manufactures plasmid DNA, mRNA and proteins for biotechnology and pharmaceutical customers across research, clinical and commercial applications. Get the full story at our sister site, Pharmaceutical Processing World.